Skip to content

13F-HR filed by BVF INC/IL

BVF INC/IL filed this 13F-HR for the quarter ended 2015-12-31, filed 2016-02-16, with 30 holding rows worth $586,783,000.

Accession
0000921895-16-003386
Filed
2016-02-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2015

A holdings report, 30 entries on the cover page, a total value of $586,783,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $586,783,000 with VALUE read as thousands by filing date, 13F file number 028-06800. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BLUEPRINT MEDICINES CORP09627Y109COM2,278,459$60,015,000thousands by filing date
CHEMOCENTRYX INC16383L106COM6,677,722$54,090,000thousands by filing date
CTI BIOPHARMA CORP COM NEW12648L106Stock43,795,613$53,869,000thousands by filing date
CONCERT PHARMACEUTICALS INC206022105COM2,232,014$42,341,000thousands by filing date
ONCOTHYREON INC682324108COM18,799,368$41,735,000thousands by filing date
VITAE PHARMACEUTICALS INC92847N103COM2,061,325$37,310,000thousands by filing date
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK2,935,975$34,028,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW2,920,628$30,550,000thousands by filing date
ARRAY BIOPHARMA INC COM04269X105Stock6,682,711$28,201,000thousands by filing date
FORWARD PHARMA A/S34986J105SPONSORED ADR1,441,287$27,384,000thousands by filing date
ONCOMED PHARMACEUTICALS INC COM68234X102Stock991,433$22,347,000thousands by filing date
EXELIXIS INC30161QAC8NOTE 4.250% 8/118,842,778$22,187,000thousands by filing dateprincipal
LOXO ONCOLOGY INC548862101COM711,067$20,230,000thousands by filing date
ARQULE INC04269E107COM6,809,843$14,777,000thousands by filing date
QLT INC746927102COMMON STOCK5,364,385$14,269,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK608,848$12,707,000thousands by filing date
TOBIRA THERAPEUTICS INC COM88883P101COM1,253,401$12,597,000thousands by filing date
FIVE PRIME THERAPEUTICS INC.33830X104Common Stock300,000$12,450,000thousands by filing date
NIVALIS THERAPEUTICS INC65481J109COM1,195,013$9,249,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock1,125,572$9,050,000thousands by filing date
GTX INC40052B108COM11,163,136$7,814,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328601COM NEW4,777,381$4,288,000thousands by filing date
PAIN THERAPEUTICS INC69562K100COM1,852,353$3,242,000thousands by filing date
CATALYST14888D109COM970,948$3,039,000thousands by filing date
GLOBEIMMUNE INC37957B100COM657,653$2,539,000thousands by filing date
ARRAY BIOPHARMA INC04269XAA3NOTE 3.000% 6/02,500,000$2,327,000thousands by filing dateprincipal
MAST THERAPEUTICS INC576314108COM3,696,961$1,554,000thousands by filing date
CALITHERA BIOSCIENCES INC COM NEW13089P101Stock167,900$1,286,000thousands by filing date
BIOTA PHARMACEUTIALS INC090694100COM350,776$681,000thousands by filing date
NEPHROGENEX INC640667101Cmn392,156$627,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000921895-16-003386this filing2016-02-16acceptance time not in the bulk data set